blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2912193

EP2912193 - PREDICTIVE MARKERS FOR POLYAMINE INHIBITOR CANCER THERAPIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.07.2019
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  27.07.2018
FormerGrant of patent is intended
Status updated on  22.03.2018
FormerExamination is in progress
Status updated on  16.12.2016
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Arizona Board of Regents on Behalf of University of Arizona
220 W. Sixth St.
Tucson, AZ 85721 / US
[2015/36]
Inventor(s)01 / GERNER, Eugene
1780 W. Sunset
Tucson, AZ 85704 / US
02 / PAZ, Edwin
2002 E. River Road, R12
Tucson, AZ 85718 / US
03 / LAFLEUR, Bonnie
4151 W. Speedway Blvd.
Tucson, AZ 85725 / US
04 / GARCIA-HUIDOBRO, Jenaro
5051 N. Apache Hills Trail
Tucson, AZ 85750 / US
 [2015/36]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2018/35]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Former [2015/36]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Application number, filing date13786402.129.10.2013
[2015/36]
WO2013US67305
Priority number, dateUS201261719748P29.10.2012         Original published format: US 201261719748 P
[2015/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014070767
Date:08.05.2014
Language:EN
[2014/19]
Type: A1 Application with search report 
No.:EP2912193
Date:02.09.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 08.05.2014 takes the place of the publication of the European patent application.
[2015/36]
Type: B1 Patent specification 
No.:EP2912193
Date:29.08.2018
Language:EN
[2018/35]
Search report(s)International search report - published on:EP08.05.2014
ClassificationIPC:C12Q1/68, G01N33/574, C12Q1/18, A61K31/192, A61K31/196, A61K31/198, A61K31/616, A61K31/635, C12Q1/6886, A61K45/06
[2018/15]
CPC:
C12Q1/6886 (EP,US); G01N33/57595 (US); A61K31/192 (EP,US);
A61K31/196 (EP,US); A61K31/198 (EP,US); A61K31/616 (EP,US);
A61K31/635 (EP,US); A61K45/06 (EP,US); C12Q1/18 (EP,US);
G01N33/5759 (EP,US); C12Q2600/106 (EP,US); C12Q2600/156 (EP,US);
C12Q2600/158 (EP,US); C12Q2600/178 (EP,US); G01N2333/4703 (US);
G01N2800/52 (EP,US) (-)
C-Set:
A61K31/192, A61K2300/00 (EP,US);
A61K31/196, A61K2300/00 (US,EP);
A61K31/198, A61K2300/00 (US,EP);
A61K31/616, A61K2300/00 (EP,US);
A61K31/635, A61K2300/00 (US,EP)
(-)
Former IPC [2015/36]C12Q1/68, G01N33/574
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/36]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:PRÄDIKTIVE MARKER FÜR KREBSTHERAPIEN MIT POLYAMININHIBITOR[2015/36]
English:PREDICTIVE MARKERS FOR POLYAMINE INHIBITOR CANCER THERAPIES[2015/36]
French:MARQUEURS DE PRÉDICTION POUR DES THÉRAPIES ANTICANCÉREUSES PAR INHIBITEUR DE POLYAMINE[2015/36]
Entry into regional phase29.05.2015National basic fee paid 
29.05.2015Designation fee(s) paid 
29.05.2015Examination fee paid 
Examination procedure29.05.2015Examination requested  [2015/36]
21.12.2015Amendment by applicant (claims and/or description)
15.12.2016Despatch of a communication from the examining division (Time limit: M06)
15.06.2017Reply to a communication from the examining division
15.02.2018Cancellation of oral proceeding that was planned for 23.04.2018
21.03.2018Communication of intention to grant the patent
23.04.2018Date of oral proceedings (cancelled)
20.07.2018Fee for grant paid
20.07.2018Fee for publishing/printing paid
20.07.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.12.2016
Opposition(s)31.05.2019No opposition filed within time limit [2019/32]
Fees paidRenewal fee
07.08.2015Renewal fee patent year 03
11.10.2016Renewal fee patent year 04
11.10.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL29.08.2018
CY29.08.2018
EE29.08.2018
HR29.08.2018
LV29.08.2018
MC29.08.2018
MK29.08.2018
RS29.08.2018
SK29.08.2018
SM29.08.2018
MT29.10.2018
BG29.11.2018
IS29.12.2018
[2020/31]
Former [2020/08]AL29.08.2018
EE29.08.2018
HR29.08.2018
LV29.08.2018
MC29.08.2018
RS29.08.2018
SK29.08.2018
SM29.08.2018
MT29.10.2018
BG29.11.2018
IS29.12.2018
Former [2019/28]AL29.08.2018
EE29.08.2018
HR29.08.2018
LV29.08.2018
MC29.08.2018
RS29.08.2018
SK29.08.2018
SM29.08.2018
BG29.11.2018
IS29.12.2018
Former [2019/27]AL29.08.2018
EE29.08.2018
HR29.08.2018
LV29.08.2018
RS29.08.2018
SK29.08.2018
SM29.08.2018
BG29.11.2018
IS29.12.2018
Former [2019/24]AL29.08.2018
EE29.08.2018
HR29.08.2018
LV29.08.2018
RS29.08.2018
SK29.08.2018
BG29.11.2018
IS29.12.2018
Former [2019/12]AL29.08.2018
HR29.08.2018
LV29.08.2018
RS29.08.2018
BG29.11.2018
IS29.12.2018
Former [2019/11]HR29.08.2018
RS29.08.2018
BG29.11.2018
IS29.12.2018
Former [2019/08]IS29.12.2018
Cited inInternational search[XYI]   THOMPSON P A ET AL: "Levels of Rectal Mucosal Polyamines and Prostaglandin E2 Predict Ability of DFMO and Sulindac to Prevent Colorectal Adenoma", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 139, no. 3, 1 September 2010 (2010-09-01), pages 797 - 805.e1, XP027271788, ISSN: 0016-5085, [retrieved on 20100609] [X] 84,85 * abstract * * page 800, column 1, paragraph 4 - page 801, column 2, paragraph 1 * * page 803, column 2 *[Y] 97-99 [I] 1-83,86-89
 [XYI]   VICTOR A. LEVIN ET AL: "Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy", INTERNATIONAL JOURNAL OF CANCER, vol. 121, no. 10, 15 November 2007 (2007-11-15), pages 2279 - 2283, XP055092930, ISSN: 0020-7136, DOI: 10.1002/ijc.22914 [X] 84,85 * abstract *[Y] 97-99 [I] 1-83,86-89

DOI:   http://dx.doi.org/10.1002/ijc.22914
 [XP]   EDWIN A. PAZ ET AL: "Polyamines are oncometabolites that regulate the LIN28/let-7 pathway in colorectal cancer cells", MOLECULAR CARCINOGENESIS, 4 May 2013 (2013-05-04), pages n/a - n/a, XP055089995, ISSN: 0899-1987, DOI: 10.1002/mc.22051 [XP] 1-99 * the whole document *

DOI:   http://dx.doi.org/10.1002/mc.22051
Examination  HIXSON L J ET AL: "Sources of variability in estimating ornithine decarboxylase activity and polyamine contents in human colorectal mucosa.", CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION : A PUBLICATION OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, COSPONSORED BY THE AMERICAN SOCIETY OF PREVENTIVE ONCOLOGY JUN 1994, vol. 3, no. 4, June 1994 (1994-06-01), pages 317 - 323, ISSN: 1055-9965
   LOZIER ANN M ET AL: "Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma.", ONCOTARGET 01 JAN 2015, vol. 6, no. 1, 1 January 2015 (2015-01-01), pages 196 - 206, ISSN: 1949-2553 [P]
by applicant  ALBERTS ET AL., J. CELL. BIOCHEM. SUPP., 1995, pages 18 - 23
   AMA DRUG EVALUATIONS ANNUAL, 1994, pages 1814 - 1815
   BABBAR ET AL., BIOCHEM. J., vol. 394, 2006, pages 317 - 24
   BAILEY ET AL., CANCER PREV RES (PHILA, vol. 3, 2010, pages 35 - 47
   BARRY, J. NATL. CANCER INST., vol. 98, no. 20, 2006, pages 1494 - 500
   BEDI ET AL., CANCER RES., vol. 55, no. 9, 1995, pages 1811 - 1816
   BELLOFERNANDEZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 7804 - 8
   BUECHNER ET AL., BR J CANCER, vol. 105, 2011, pages 296 - 303
   CARAGLIA ET AL., AMINO ACIDS, 3 December 2011 (2011-12-03)
   CHILDS ET AL., CELL. MOLEC. LIFE SCI., vol. 60, 2003, pages 1394 - 1406
   DERYNCK ET AL., NATURE GENETICS, vol. 29, 2001, pages 117 - 29
   DUBOIS ET AL., CANCER RES., vol. 56, 1996, pages 733 - 737
   ERDMAN ET AL., CARCINOGENESIS, vol. 20, 1999, pages 1709 - 13
   FILIPOWICZ ET AL., NAT REV GENET, vol. 9, 2008, pages 102 - 14
   FULTZ; GERNER, MOL. CARCINOG., vol. 34, 2002, pages 10 - 8
   FUSCO, A.; FEDELE, M., NAT REV CANCER, vol. 7, 2007, pages 899 - 910
   GERNER, E.W.; MEYSKENS, F.L., JR., NAT REV CANCER, vol. 4, 2004, pages 781 - 92
   GERNER ET AL., CANCER EPIDEMOIL. BIOMARKERS PREV., vol. 3, 1994, pages 325 - 330
   GIARDIELLO ET AL., CANCER RES., 1997, pages 199 - 201
   GUO ET AL., CANCER RES., vol. 60, no. 22, 2000, pages 6314 - 6317
   HANIF ET AL., BIOCHEMICAL PHARMACOLOGY, 1996, pages 237 - 245
   HEO ET AL., CELL, vol. 138, 2009, pages 696 - 708
   HOGARTY ET AL., CANCER RES, vol. 68, 2008, pages 9735 - 45
   HUBNER ET AL., CLIN. CANCER RES., vol. 14, no. 8, 2008, pages 2303 - 9
   IGNATENKO ET AL., CANCER BIOL. THER., vol. 5, no. 12, 2006, pages 1658 - 64
   IWAMOTO ET AL., CARCINOGENESIS, vol. 21, 2000, pages 1935 - 40
   JOHNSON ET AL., NAT. GENET., vol. 29, no. 2, 2001, pages 233 - 237
   JOHNSON ET AL., CANCER RES, vol. 67, 2007, pages 7713 - 22
   KINGSNORTH ET AL., CANCER RES., vol. 43, no. 9, 1983, pages 4035 - 8
   KUMAR ET AL., PROC NATL ACAD SCI USA, vol. 105, 2008, pages 3903 - 8
   LADENHEIM ET AL., GASTROENTEROLOGY, vol. 108, 1995, pages 1083 - 1087
   LANDAU ET AL., JBIOL CHEM, vol. 285, 2010, pages 12474 - 81
   LANZA ET AL., ARCH. INTERN. MED., vol. 155, 1995, pages 1371 - 1377
   LEE, Y.S.; DUTTA, A., GENES DEV, vol. 21, 2007, pages 1025 - 30
   LIPKIN, J., CELL BIOCHEM., vol. 28-29, 1997, pages 144 - 7
   LOVE ET AL., J. NATL. CANCER INST., vol. 85, 1993, pages 732 - 7
   LUK; BAYLIN, N. ENGL. J. MED., vol. 311, no. 2, 1984, pages 80 - 83
   LUPULESCU, CANCER DETECT. PREV., vol. 20, no. 6, 1996, pages 634 - 637
   MARTINEZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 100, 2003, pages 7859 - 64
   MATSUBARA ET AL., CLINICAL CANCER RES., vol. 1, 1995, pages 665 - 71
   MAYR ET AL., SCIENCE, vol. 315, 2007, pages 1576 - 9
   MCLAREN ET AL., CANCER PREV. RES., vol. 1, no. 7, 2008, pages 514 - 21
   MEYSKENS ET AL., J NATL. CANCER INST., vol. 86, no. 15, 1994, pages 1122 - 1130
   MEYSKENS ET AL., J. NATL. CANCER INST., vol. 90, no. 16, 1998, pages 1212 - 8
   MEYSKENS ET AL.: "Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial", CANCER PREV RES (PHILA, vol. 1, 2008, pages 32 - 8
   MUSCAT ET AL., CANCER, vol. 74, 1994, pages 1847 - 1854
   NARISAWA ET AL., CANCER RES., vol. 41, no. 5, 1981, pages 1954 - 1957
   OBAD ET AL., NAT GENET, vol. 43, 2011, pages 371 - 8
   O'BRIEN ET AL., MOLEC. CARCINOG., vol. 41, no. 2, 2004, pages 120 - 3
   PARDALI; MOUSTAKAS, BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1775, 2007, pages 21 - 62
   PARK ET AL., AMINO ACIDS, vol. 38, 2009, pages 491 - 500
   PEGG, BIOCHEM., vol. 234, no. 2, 1986, pages 249 - 262
   PHYSICIAN'S DESK REFERENCE, MEDICAL ECONOMICS DATA, 1999, pages 1745 - 1747
   PIAZZA ET AL., CANCER RES., 1995, pages 3116
   PIAZZA ET AL., CANCER RES., 1997, pages 2452 - 2459
   PIAZZA ET AL., CANCER RES., 1997, pages 2909 - 2915
   POLLARD; LUCKERT, CANCER RES., vol. 49, 1989, pages 6471 - 6473
   RAO ET AL., CANCER RES., 1995, pages 1464 - 1472
   REDDY ET AL., CANCER RES., 1990, pages 2562 - 2568
   REDDY ET AL., CANCER RES., vol. 47, 1987, pages 5340 - 5346
   REINHART ET AL., NATURE, vol. 403, 2000, pages 901 - 6
   ROBERTS; WAKEFIELD, PROC. NATL. ACAD. SCI. USA, vol. 100, 2003, pages 8621 - 3
   ROUSH, S.; SLACK, F.J., TRENDS CELL BIOL, vol. 18, 2008, pages 505 - 16
   SAINI ET AL., NATURE, vol. 459, 2009, pages 118 - 21
   SAMAL ET AL., INT. J. CANCER, vol. 133, 2013, pages 1323 - 1334
   SIMONEAU ET AL., J. NATL. CANCER INST., vol. 93, 2001, pages 57 - 9
   SIMONEAU ET AL., CANCER EPIDEMIOL BIOMARKERS PREV, vol. 17, 2008, pages 292 - 9
   SINGH; REDDY, ANNALS. NYACAD. SCI., 1995, pages 205 - 209
   SINGH ET AL., CARCINOGENESIS, 1994, pages 1317 - 1323
   SPORN, M.B.; HONG, W.K., NAT CLIN PRACT ONCOL, vol. 5, 2008, pages 628 - 9
   STREJAN ET AL., CELL IMMUNOL., vol. 84, no. 1, 1984, pages 171 - 184
   SU, SCIENCE, 1992, pages 668 - 670
   TEMPERO ET AL., CANCER RES., vol. 49, no. 21, 1989, pages 5793 - 7
   THOMAS; THOMAS, J. CELL MOL. MED., vol. 7, 2003, pages 113 - 26
   THOMPSON ET AL., J. NATL CANCER INST., 1995, pages 125 - 1260
   VANDER HEIDEN, M.G., NAT REV DRUG DISCOV, vol. 10, 2011, pages 671 - 84
   VANE; BOTTING, ADV EXP MED BIOL., vol. 433, 1997, pages 131 - 8
   VISWANATHAN ET AL., J. UROL., vol. 171, 2004, pages 652 - 5
   VISWANATHAN, S.R.; DALEY, G.Q., CELL, vol. 140, 2010, pages 445 - 9
   VISWANATHAN ET AL., SCIENCE, vol. 320, 2008, pages 97 - 100
   WALLACE, EUR. J. CLIN. INVEST., vol. 30, 2000, pages 1 - 3
   WANG ET AL., CLIN CANCER RES, vol. 17, 2011, pages 2570 - 80
   WATANABE ET AL., JBIOL CHEM, vol. 266, 1991, pages 20803 - 9
   YANG ET AL., CANCER RES, vol. 68, 2008, pages 10307 - 14
   ZHANG ET AL., GENES DEV, vol. 26, 2012, pages 461 - 73
   ZELL ET AL., CANCER PREV. RES., vol. 2, no. 3, 2009, pages 209 - 12
   ZELL ET AL., CLIN. CANCER RES., vol. 15, no. 19, 2009, pages 6208 - 16
   ZENDER ET AL., CELL, vol. 135, 2008, pages 852 - 64
   ZHU ET AL., CELL, vol. 147, 2011, pages 81 - 94
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.